ASX 200 set to rise – CSL, WBC & NCM shares in focus
Drew Meredith, CFP
October 13, 2021
The S&P/ASX 200 (ASX: XJO) fell 0.3% on Tuesday as
CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
The S&P/ASX 200 (ASX: XJO) fell 0.3% on Tuesday as
Today CSL Limited (ASX: CSL) held its Annual General Meeting
Could ASX blue chip shares be some of the best
The S&P/ASX 200 (ASX: XJO) fell another 1.5% on Tuesday
BetaShares Australia 200 ETF (ASX:A200) could be a really good
Could Australian Foundation Investment Co. Ltd. (ASX:AFI) be a great
The S&P/ASX 200 fell 0.8% on Friday, erasing the week’s
The S&P/ASX 200 (ASX: XJO) dropped another 0.3% on Wednesday
Might the CSL Limited (ASX:CSL) share price be an opportunity
Want to level-up your analytical skills and investing insights but don’t know where to start? Join 50,000 Australian investors on our mailing list and we’ll send you our favourite podcasts, courses, resources and investment articles every Sunday morning. Grab a coffee and let Owen and the team bring you the best insights.
By downloading, you agree to receive emails from us. You can unsubscribe anytime.
Here you go: A $50,000 per year passive income special report
Join more 50,000 Australian investors who read our weekly investing newsletter and we’ll send you our passive income investing report right now.
Simply enter your email address and we’ll send it to you. No tricks. Unsubscribe anytime.
Read our Terms, Financial Services Guide, Privacy Policy. We’ll never sell your email address. Our company is Australian owned.